Page 45 - NPPA full book

Over the years, India has con nued its successful vaccines developments and some of the important ones since 2012 are as
follows:

Typbar, vaccine for typhoid launched by Bharat Biotech in

2013.

Rotavirus Vaccine: In 2015, India launched its indigenous

rotavirus vaccine, Rotavac, developed by Bharat Biotech.

This vaccine is effec ve against rotavirus, a major cause of
diarrhoea in children.

IPV Vaccine: In 2015, India introduced the inac vated

polio vaccine (IPV) as part of its immuniza on program to

supplement the oral polio vaccine (OPV). This move aimed Unveiling of Rotavirus vaccine on 9th March 2015 by
Shri Narendra Modi, Prime Minister of India
to eliminate polio and strengthen the country’s polio eradica on efforts.

Measles-Rubella Vaccine: In 2017, the Indian government launched a na onwide campaign to administer the measles-rubella
New DPT-cGMP manufacturing facility at CRI, Kasauli (MR) vaccine to children between 9 months and 15 years of age. This ini a ve aimed to eliminate measles and control rubella in

the country.

Launch of world’s first fully-liquid wP_based Hexavalent vaccine by Panacea Biotech in 2017.

In 2019, the whole world was hit by the COVID-19 virus and this period saw a rapid development in the pharmaceu cal sector

with a focus on vaccine(s) development. In 2021, Bharat Biotech Interna onal Limited (BBIL) introduced Covaxin , in

conjunc on with the Indian Council of Medical Research (ICMR) - Na onal Ins tute of Virology (NIV). Serum Ins tute of India,

in partnership with the University of Oxford and AstraZeneca, developed Covishield , a COVID-19 vaccine based on the viral

vector pla orm.

Covishield and Covaxin have been a crucial component of

Panacea Biotech Bharat Biotech
India’s vaccination drive to control COVID

34 35